[go: up one dir, main page]

WO1991015466A3 - Agents chelateurs - Google Patents

Agents chelateurs Download PDF

Info

Publication number
WO1991015466A3
WO1991015466A3 PCT/EP1991/000674 EP9100674W WO9115466A3 WO 1991015466 A3 WO1991015466 A3 WO 1991015466A3 EP 9100674 W EP9100674 W EP 9100674W WO 9115466 A3 WO9115466 A3 WO 9115466A3
Authority
WO
WIPO (PCT)
Prior art keywords
chelating agents
acid chelating
aminopolycarboxylic acid
chelants
aminopolycarboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1991/000674
Other languages
English (en)
Other versions
WO1991015466A2 (fr
Inventor
Paal Rongved
Jo Klaveness
Harald Dugstad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed AS filed Critical Nycomed AS
Publication of WO1991015466A2 publication Critical patent/WO1991015466A2/fr
Publication of WO1991015466A3 publication Critical patent/WO1991015466A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention a pour objet des agents chelateurs de formule (I) (décrits dans la revendication 1). Ceux-ci s'adressent particulièremnt à la production d'agents thérapeutiques, de diagnostic et de détoxication.
PCT/EP1991/000674 1990-04-09 1991-04-09 Agents chelateurs Ceased WO1991015466A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909007965A GB9007965D0 (en) 1990-04-09 1990-04-09 Compounds
GB9007965.8 1990-04-09

Publications (2)

Publication Number Publication Date
WO1991015466A2 WO1991015466A2 (fr) 1991-10-17
WO1991015466A3 true WO1991015466A3 (fr) 1991-11-28

Family

ID=10674118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/000674 Ceased WO1991015466A2 (fr) 1990-04-09 1991-04-09 Agents chelateurs

Country Status (3)

Country Link
AU (1) AU7661991A (fr)
GB (1) GB9007965D0 (fr)
WO (1) WO1991015466A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19507820A1 (de) * 1995-02-21 1996-08-22 Schering Ag Neuartig substituierte DTPA-Derivate, deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
CA2447695C (fr) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Anticorps modifies diriges contre l'antigene prostatique specifique membranaire et utilisations associees
WO2003024388A2 (fr) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methodes et compositions de traitement ou de prevention de troubles cutanes au moyen d'agents de liaison specifiques pour un antigene membranaire specifique de la prostate
ES2314272T3 (es) 2003-01-10 2009-03-16 Millennium Pharmaceuticals, Inc. Metodos para el diagnostico y el tratamiento del cancer.
FI20065030L (fi) * 2006-01-17 2007-07-18 Wallac Oy Neutraaliset leimausreagenssit ja niistä johdetut konjugaatit
HUP1500076A2 (hu) * 2015-02-25 2016-09-28 Debreceni Egyetem Új helyettesített etilén-diamin-tetraecetsav-bisz(amid) származékok és alkalmazásuk Mn(II)-alapú MRI kontrasztanyag ligandumként

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3324236A1 (de) * 1983-07-01 1985-01-10 Schering AG, 1000 Berlin und 4709 Bergkamen Neue komplexbildner
EP0130934B1 (fr) * 1983-07-01 1987-08-05 Schering Aktiengesellschaft Agents complexants, complexes et sels complexes
EP0263059A2 (fr) * 1986-09-26 1988-04-06 Schering Aktiengesellschaft Amides complexes
EP0299795A2 (fr) * 1987-07-16 1989-01-18 Nycomed As Acides aminopolycarboxyliques et leurs dérivés
US4826673A (en) * 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
WO1990001024A1 (fr) * 1988-07-19 1990-02-08 Mallinckrodt, Inc. Agents d'imagerie a resonance magnetique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3324236A1 (de) * 1983-07-01 1985-01-10 Schering AG, 1000 Berlin und 4709 Bergkamen Neue komplexbildner
EP0130934B1 (fr) * 1983-07-01 1987-08-05 Schering Aktiengesellschaft Agents complexants, complexes et sels complexes
US4826673A (en) * 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
EP0263059A2 (fr) * 1986-09-26 1988-04-06 Schering Aktiengesellschaft Amides complexes
EP0299795A2 (fr) * 1987-07-16 1989-01-18 Nycomed As Acides aminopolycarboxyliques et leurs dérivés
WO1990001024A1 (fr) * 1988-07-19 1990-02-08 Mallinckrodt, Inc. Agents d'imagerie a resonance magnetique

Also Published As

Publication number Publication date
AU7661991A (en) 1991-10-30
WO1991015466A2 (fr) 1991-10-17
GB9007965D0 (en) 1990-06-06

Similar Documents

Publication Publication Date Title
CA2140106A1 (fr) Methode de traitement des affections vasculaires hyperproliferatives
CA2195213A1 (fr) Utilisation du droloxifene pour le traitement des affections cardio-vasculaires
DK0490823T3 (fr)
WO1991010645A3 (fr) Agents de chelation
CA2263561A1 (fr) Thienopyrimidines
AU7272291A (en) Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
NO912151D0 (no) Essensiell-fettsyre-behandling.
AU6673894A (en) Super tir-tac-poc tossing game
DE69905368D1 (en) Oxydiertes thymosin beta 4
EP0542914A4 (en) Improved diagnostic and therapeutic compositions
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
IE791235L (en) Acyl-derivatives of carnitine.
IL97426A0 (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
OA09194A (en) "Insecticidal treatment and compositions therefor".
WO1991015466A3 (fr) Agents chelateurs
GR3006349T3 (fr)
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
CA2078700A1 (fr) Imidazolylmethyl-pyridines
GR3017967T3 (en) Substituted pyrido-oxazines.
AU2904789A (en) Macrocyclic chelating agents and chelates thereof
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis
AU7675587A (en) Photosensitizers and polymerizable compositions
CA2101548A1 (fr) Acides acylamino-alylidenehydroxy-bisphosphoniques, utiles pour le traitement des maladies osteoarticulaires
IE810311L (en) Guanylamidines.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER THE COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

NENP Non-entry into the national phase

Ref country code: CA